Identification of a ferroptosis-related gene signature for predicting the prognosis of cholangiocarcinoma

References

• Rizvi S, Khan SA, Hallemeier CL, et al. Cholangiocarcinoma - evolving concepts and therapeutic strategies. Nat Rev Clin Oncol. 2018 Feb;15(2):95–111.
   PubMed Web of Science ®Google Scholar
• Valle JW, Borbath I, Khan SA, et al. Biliary cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2016 Sep;27(suppl 5):v28–v37.
   PubMed Web of Science ®Google Scholar
• Mazzaferro V, Gorgen A, Roayaie S, et al. Liver resection and transplantation for intrahepatic cholangiocarcinoma. J Hepatol. 2020;72(2):364–377.
   PubMed Web of Science ®Google Scholar
• Valle J, Wasan H, Palmer DH, et al. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med. 2010;362:1273–1281.
   PubMed Web of Science ®Google Scholar
• Valle JW, Kelley RK, Nervi B, et al. Biliary tract cancer. Lancet. 2021;397(10272):428–444.
   PubMed Web of Science ®Google Scholar
• Sui M, Li Y, Wang H, et al. Two cases of intrahepatic cholangiocellular carcinoma with high insertion-deletion ratios that achieved a complete response following chemotherapy combined with PD-1 blockade. J Immunother Cancer. 2019;7(1):125.
   PubMed Web of Science ®Google Scholar
• Gbolahan O, Hashemi-Sadraei N, O’Neil B. Prolonged response to anti–PD-1 antibody therapy in chemotherapy-refractory cholangiocarcinoma with high tumor mutational burden. J National Compr Cancer Network. 2019;17(6):644–648.
   PubMed Web of Science ®Google Scholar
• Jakubowski CD, Azad NS. Immune checkpoint inhibitor therapy in biliary tract cancer (cholangiocarcinoma). Chin Clin Oncol. 2020;9(1):2.
   PubMed Web of Science ®Google Scholar
• Dixon SJ, Lemberg KM, Lamprecht MR, et al. Ferroptosis: an iron-dependent form of nonapoptotic cell death. Cell. 2012 May 25;149(5):1060–1072.
   PubMed Web of Science ®Google Scholar
• Lei G, Zhang Y, Koppula P, et al. The role of ferroptosis in ionizing radiation-induced cell death and tumor suppression. Cell Res. 2020;30(2):146–162.
   PubMed Web of Science ®Google Scholar
• Shen Z, Song J, Yung BC, et al. Emerging strategies of cancer therapy based on ferroptosis. Adv Mater. 2018 Mar;30(12):e1704007.
   PubMed Web of Science ®Google Scholar
• Stockwell BR, Friedmann Angeli JP, Bayir H, et al. Ferroptosis: a regulated cell death nexus linking metabolism, redox biology, and disease. Cell. 2017 Oct 5;171(2):273–285.
   PubMed Web of Science ®Google Scholar
• Hassannia B, Vandenabeele P, Vanden Berghe T. Targeting ferroptosis to iron out cancer. Cancer Cell. 2019 Jun 10;35(6):830–849.
   PubMed Web of Science ®Google Scholar
• Jiang L, Kon N, Li T, et al. Ferroptosis as a p53-mediated activity during tumour suppression. Nature. 2015 Apr 2;520(7545):57–62.
   PubMed Web of Science ®Google Scholar
• Kim EH, Shin D, Lee J, et al. CISD2 inhibition overcomes resistance to sulfasalazine-induced ferroptotic cell death in head and neck cancer. Cancer Lett. 2018 Sep 28;432:180–190.
   PubMed Web of Science ®Google Scholar
• Doll S, Proneth B, Tyurina YY, et al. ACSL4 dictates ferroptosis sensitivity by shaping cellular lipid composition. Nat Chem Biol. 2017 Jan;13(1):91–98.
   PubMed Web of Science ®Google Scholar
• Zou Y, Palte MJ, Deik AA, et al. A GPX4-dependent cancer cell state underlies the clear-cell morphology and confers sensitivity to ferroptosis. Nat Commun. 2019;10(1):1617.
   PubMed Web of Science ®Google Scholar
• Wang W, Green M, Choi JE, et al. CD8(+) T cells regulate tumour ferroptosis during cancer immunotherapy. Nature. 2019 May;569(7755):270–274.
   PubMed Web of Science ®Google Scholar
• Andersen JB, Spee B, Blechacz BR, et al. Genomic and genetic characterization of cholangiocarcinoma identifies therapeutic targets for tyrosine kinase inhibitors. Gastroenterology. 2012 Apr;142(4):1021–31 e15.
   PubMed Web of Science ®Google Scholar
• Chaisaingmongkol J, Budhu A, Dang H, et al. Common molecular subtypes among asian hepatocellular carcinoma and cholangiocarcinoma. Cancer Cell. 2017 Jul 10;32(1):57–70e3.
   PubMed Web of Science ®Google Scholar
• Sia D, Hoshida Y, Villanueva A, et al. Integrative molecular analysis of intrahepatic cholangiocarcinoma reveals 2 classes that have different outcomes. Gastroenterology. 2013 Apr;144(4):829–840.
   PubMed Web of Science ®Google Scholar
• Ahn KS, O’Brien D, Kang YN, et al. Prognostic subclass of intrahepatic cholangiocarcinoma by integrative molecular-clinical analysis and potential targeted approach. Hepatol Int. 2019 Jul;13(4):490–500.
   PubMed Web of Science ®Google Scholar
• Uhlen M, Zhang C, Lee S, et al. A pathology atlas of the human cancer transcriptome. Science. 2017 Aug 18;357(6352):eaan2507.
   PubMed Web of Science ®Google Scholar
• Uhlen M, Fagerberg L, Hallstrom BM, et al. Proteomics. Tissue-based map of the human proteome. Science. 2015 Jan 23;347(6220):1260419.
   PubMed Web of Science ®Google Scholar
• Zhou N, Bao J. FerrDb: a manually curated resource for regulators and markers of ferroptosis and ferroptosis-disease associations. Database (Oxford). 2020 Jan 1;2020:baaa021.
   PubMed Web of Science ®Google Scholar
• Ye Y, Dai Q, Li S, et al. A novel defined risk signature of the ferroptosis-related genes for predicting the prognosis of ovarian cancer. Front Mol Biosci. 2021;8:645845.
   PubMed Web of Science ®Google Scholar
• Liang JY, Wang DS, Lin HC, et al. A novel ferroptosis-related gene signature for overall survival prediction in patients with hepatocellular carcinoma. Int J Biol Sci. 2020;16(13):2430–2441.
   PubMed Web of Science ®Google Scholar
• Wang D, Wei G, Ma J, et al. Identification of the prognostic value of ferroptosis-related gene signature in breast cancer patients. BMC Cancer. 2021 May 31;21(1):645.
   PubMed Web of Science ®Google Scholar
• Szklarczyk D, Gable AL, Lyon D, et al. STRING v11: protein-protein association networks with increased coverage, supporting functional discovery in genome-wide experimental datasets. Nucleic Acids Res. 2019 Jan 8;47(D1):D607–13.
   PubMed Web of Science ®Google Scholar
• Zhou Y, Zhou B, Pache L, et al. Metascape provides a biologist-oriented resource for the analysis of systems-level datasets. Nat Commun. 2019 Apr 3;10(1):1523.
   PubMed Web of Science ®Google Scholar
• Yoshihara K, Shahmoradgoli M, Martinez E, et al. Inferring tumour purity and stromal and immune cell admixture from expression data. Nat Commun. 2013;4:2612.
   PubMed Web of Science ®Google Scholar
• Guo H, Cai J, Wang X, et al. Prognostic values of a novel multi-mRNA signature for predicting relapse of cholangiocarcinoma. Int J Biol Sci. 2020;16(5):869–881.
   PubMed Web of Science ®Google Scholar
• Zou W, Wang Z, Wang F, et al. A metabolism-related 4-lncRNA prognostic signature and corresponding mechanisms in intrahepatic cholangiocarcinoma. BMC Cancer. 2021 May 25;21(1):608.
   PubMed Web of Science ®Google Scholar
• Chen D, Wu H, He B, et al. Five hub genes can be the potential DNA methylation biomarkers for cholangiocarcinoma using bioinformatics analysis. Onco Targets Ther. 2019;12:8355–8365.
   PubMed Web of Science ®Google Scholar
• Yang BC, Leung PS. Irisin is a positive regulator for ferroptosis in pancreatic cancer. Mol Ther Oncolytics. 2020 Sep;25(18):457–466.
   Web of Science ®Google Scholar
• Lu T, Xu R, Li Q, et al. Systematic profiling of ferroptosis gene signatures predicts prognostic factors in esophageal squamous cell carcinoma. Mol Ther Oncolytics. 2021 Jun;25(21):134–143.
   Web of Science ®Google Scholar
• Huang W, Duan Y, Yang X, et al. Identification of novel prognostic risk signatures of soft tissue sarcoma based on ferroptosis-related genes. Front Oncol. 2021;11:629868.
   PubMed Web of Science ®Google Scholar
• Shui S, Zhao Z, Wang H, et al. Non-enzymatic lipid peroxidation initiated by photodynamic therapy drives a distinct ferroptosis-like cell death pathway. Redox Biol. 2021;45:102056.
   PubMed Web of Science ®Google Scholar
• Chen J, Ding C, Chen Y, et al. ACSL4 reprograms fatty acid metabolism in hepatocellular carcinoma via c-Myc/SREBP1 pathway. Cancer Lett. 2021 Apr 1;502:154–165.
   PubMed Web of Science ®Google Scholar
• Magtanong L, Ko PJ, To M, et al. Exogenous monounsaturated fatty acids promote a ferroptosis-resistant cell state. Cell Chem Biol. 2019 Mar 21;26(3):420–32 e9.
   PubMed Web of Science ®Google Scholar
• Zhang A, Yang J, Ma C, et al. Development and validation of a robust ferroptosis-related prognostic signature in lung adenocarcinoma. Front Cell Dev Biol. 2021;24(9):616271.
   Web of Science ®Google Scholar
• Ndiaye H, Liu JY, Hall A, et al. Immunohistochemical staining reveals differential expression of ACSL3 and ACSL4 in hepatocellular carcinoma and hepatic gastrointestinal metastases. Biosci Rep. 2020 Apr 30;40(4):BSR20200219.
   PubMed Web of Science ®Google Scholar
• Li Y, Shao H, Da Z, et al. High expression of SLC38A1 predicts poor prognosis in patients with de novo acute myeloid leukemia. J Cell Physiol. 2019 Nov;234(11):20322–20328.
   PubMed Web of Science ®Google Scholar
• Sharbeen G, McCarroll JA, Akerman A, et al. Cancer-associated fibroblasts in pancreatic ductal adenocarcinoma determine response to SLC7A11 inhibition. Cancer Res. 2021 Jul 1;81(13):3461–3479.
   PubMed Web of Science ®Google Scholar
• Ji X, Qian J, Rahman SMJ, et al. xCT (SLC7A11)-mediated metabolic reprogramming promotes non-small cell lung cancer progression. Oncogene. 2018 Sep;37(36):5007–5019.
   PubMed Web of Science ®Google Scholar
• Subimerb C, Pinlaor S, Khuntikeo N, et al. Tissue invasive macrophage density is correlated with prognosis in cholangiocarcinoma. Mol Med Rep. 2010 Jul-Aug;3(4):597–605.
   PubMed Web of Science ®Google Scholar
• Chen Z, Guo P, Xie X, et al. The role of tumour microenvironment: a new vision for cholangiocarcinoma. J Cell Mol Med. 2019 Jan;23(1):59–69.
   PubMed Web of Science ®Google Scholar
• Fabris L, Perugorria MJ, Mertens J, et al. The tumour microenvironment and immune milieu of cholangiocarcinoma. Liver Int. 2019 May;39(Suppl 1):63–78.
   PubMed Web of Science ®Google Scholar
• Kitano Y, Okabe H, Yamashita YI, et al. Tumour-infiltrating inflammatory and immune cells in patients with extrahepatic cholangiocarcinoma. Br J Cancer. 2018 Jan;118(2):171–180.
   PubMed Web of Science ®Google Scholar
• Kida A, Mizukoshi E, Kido H, et al. The characteristics of the immune cell profiles in peripheral blood in cholangiocarcinoma patients. Hepatol Int. 2021 Jun;15(3):695–706.
   PubMed Web of Science ®Google Scholar